

Appendix A

Number of days (administration interval) added to IV drugs to calculate treatment duration

Indication	Administrations per cycle	Cycle frequency	Number of days to add to treatment duration
Atezolizumab - Urothelial cancer	1	21 days	20 days
Avelumab – Merkel cell carcinoma	1	14 days	13 days
Avelumab with Axitinib – untreated advanced renal cell carcinoma	1	14 days	13 days
Axicabtagene ciloleucel – B-cell lymphoma and follicular lymphoma	1	Once	N/A
Cemiplimab - cutaneous squamous cell carcinoma	1	21 days	20 days
Daratumumab - multiple myeloma*	1	7 days, 14 days, 28 days	6, 7 or 14
Daratumumab with Bortezomib – multiple myeloma**	1	7 days, 21 days, 28 days	6, 20 or 27
Durvalumab - NSCLC	1	14 days	13 days
Nivolumab - non-squamous NSCLC	1	14 days	13 days
Nivolumab - squamous*** NSCLC	1	14 or 28 days	13 or 27 days
Nivolumab - melanoma	1	14 days	13 days
Nivolumab - head and neck	1	14 days	13 days
Nivolumab with ipilimumab - renal cell carcinoma****	1 or 4	14 days, 21 days, 28 days	13, 20 or 27

Indication	Administrations per cycle	Cycle frequency	Number of days to add to treatment duration
Obinutuzumab - follicular non-Hodgkin's lymphoma	3 (day 1, 8 and 15)	28 days	7, 7 or 13
Obinutuzumab (in combination with bendamustine) - follicular non-Hodgkin's lymphoma*****	1 or 3	28 days	27 days
Olaratumab - soft tissue sarcoma	2 (day 1 and 8)	21 days	7 or 13
Pembrolizumab - urothelial cancer 1 st line	1	21 days	20 days
Pembrolizumab - urothelial cancer (previously treated)	1	21 days	20 days
Pembrolizumab - classical Hodgkin lymphoma	1	21 days	20 days
Pembrolizumab - melanoma	1	21 days	20 days
Pembrolizumab with carboplatin and paclitaxel - metastatic squamous NSCLC	1	21 days	20 days
Pembrolizumab (with pemetrexed and platinum chemotherapy) - untreated metastatic non-squamous NSCLC	1	21 days	20 days
Tisagenlecleucel – Leukaemia (previously treated)	1	Once	N/A
Tisagenlecleucel - diffuse large B-cell lymphoma	1	Once	N/A

* Given by IV weekly from week 1 to 8, then given every two weeks from week 9 to 24 and every 4 weeks thereafter until disease progression.

** Given weekly for weeks 1-9, ever 3 weeks for weeks 10 to 24 and every 4 weeks from week 25 onwards.

***240 mg every 2 weeks or 480 mg every 4 weeks

****Nivolumab 3 mg/kg with ipilimumab 1 mg/kg by intravenous infusion every 3 weeks for 4 doses followed by nivolumab 480 mg every 4 weeks or 240 mg every 2 weeks (previously 3 mg/kg every 2 weeks).

*****Cycle 1: 1,000 mg on Day 1, Day 8 and Day 15 of the first 28-day treatment cycle, cycles 2–6: 1,000 mg on day 1 of each 28-day treatment cycle. Maintenance - 1,000 mg every 2 months for 2 years or until disease progression (whichever occurs first).

Figure 1: Example of how days will be added to a patient's treatment duration




Figure 1 shows that if a patient's last cycle date in SACT was the 1st April 2018 and they received just one administration for that cycle, then 7 days will be added to their treatment duration. If a patient received two administrations for that cycle, then another 7 days will be added, and finally, if a patient received all three administrations then an additional 13 days would be added to their last administration, totalling 27 from their last cycle which will cover them until day 28 when their next cycle starts.